 |
|
|
|
|
Washington Life Science Industry Directory
Target your advertising by state, region or nationwide for the same low rate
Banner Advertising | Event Advertising
Theraclone Sciences, Inc.
| | | | | Phone: | (206) 805-1600 | | Fax: | (206) 805-1699 | | Year Established: | 2004 | | Employees: | 23 | | Main Contact: | Russ Hawkinson, CFO | | | | Other Contacts: | Kristine Swiderek, Ph.D., CSO
Clifford J. Stocks, CEO
| | | | Company Description | Theraclone Sciences (formerly Spaltudaq) is a biopharmaceutical company committed to the development and commercialization of therapeutic monoclonal antibodies for the treatment of infectious disease and inflammation. Theraclone is a privately-held organization with venture investment from ARCH Venture Partners, Canaan Partners and Healthcare Ventures.
On August 1, 2013 PharmAthene and Theraclone announced an agreement for the merger of the companies in an all-stock transaction. Under terms of the agreement, PharmAthene will issue shares of common stock to Theraclone stockholders such that Theraclone stockholders will own 50% of the combined company. | |
|
|
|
|
|
|
|
